Pulmatrix Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pulmatrix in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Pulmatrix stock.
View analyst ratings for Pulmatrix or view top-rated stocks.

Wall Street analysts have given Pulmatrix a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Pulmatrix wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Pulmatrix saw a drop in short interest in July. As of July 15th, there was short interest totaling 632,500 shares, a drop of 14.2% from the June 30th total of 737,600 shares. Based on an average daily volume of 604,500 shares, the days-to-cover ratio is currently 1.0 days. Currently, 1.1% of the shares of the stock are sold short.
View Pulmatrix's Short Interest.

Pulmatrix is scheduled to release its next quarterly earnings announcement on Friday, August 6th 2021.
View our earnings forecast for Pulmatrix.

Pulmatrix, Inc. (NASDAQ:PULM) announced its quarterly earnings data on Tuesday, May, 11th. The biotechnology company reported ($0.09) earnings per share for the quarter, beating analysts' consensus estimates of ($0.10) by $0.01. The biotechnology company earned $1.39 million during the quarter. Pulmatrix had a negative trailing twelve-month return on equity of 63.93% and a negative net margin of 166.28%.
View Pulmatrix's earnings history.

Pulmatrix's stock was trading at $1.38 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PULM stock has decreased by 40.6% and is now trading at $0.8198.
View which stocks have been most impacted by COVID-19.

Shares of Pulmatrix reverse split on the morning of Wednesday, February 6th 2019. The 1-10 reverse split was announced on Tuesday, February 5th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 5th 2019. An investor that had 100 shares of Pulmatrix stock prior to the reverse split would have 10 shares after the split.

1 brokers have issued 1-year price objectives for Pulmatrix's shares. Their forecasts range from $5.00 to $5.00. On average, they expect Pulmatrix's stock price to reach $5.00 in the next year. This suggests a possible upside of 509.9% from the stock's current price.
View analysts' price targets for Pulmatrix or view top-rated stocks among Wall Street analysts.

Some companies that are related to Pulmatrix include Zynerba Pharmaceuticals (ZYNE), Terns Pharmaceuticals (TERN), Immunome (IMNM), MediciNova (MNOV), AVEO Pharmaceuticals (AVEO), Chemomab Therapeutics (CMMB), Biofrontera (BFRA), Decibel Therapeutics (DBTX), Galectin Therapeutics (GALT), Mereo BioPharma Group (MREO), Aptinyx (APTX), Corbus Pharmaceuticals (CRBP), Marker Therapeutics (MRKR), Equillium (EQ) and Gemini Therapeutics (GMTX).
View all of PULM's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Pulmatrix investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Acasti Pharma (ACST), Biocept (BIOC), Heat Biologics (HTBX), Trevena (TRVN), TherapeuticsMD (TXMD), Verastem (VSTM) and Evoke Pharma (EVOK).

Pulmatrix trades on the NASDAQ under the ticker symbol "PULM."

Shares of PULM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PULM stock can currently be purchased for approximately $0.82.

Pulmatrix has a market capitalization of $46.11 million and generates $12.63 million in revenue each year. The biotechnology company earns $-19,310,000.00 in net income (profit) each year or ($0.67) on an earnings per share basis.

Pulmatrix employs 20 workers across the globe.

The official website for Pulmatrix is www.pulmatrix.com.

Pulmatrix is headquartered at 99 HAYDEN AVENUE SUITE 390, LEXINGTON MA, 02421.

Pulmatrix's mailing address is 99 HAYDEN AVENUE SUITE 390, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-357-2333 or via email at [email protected]